[
  {
    "ts": null,
    "headline": "Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update",
    "summary": "Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA. Read a portfolio update here.",
    "url": "https://finnhub.io/api/news?id=7ec5e1a10869fd2ac0edf332e5cc9731271a2844e308c8ff8479d01288fa561f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741728555,
      "headline": "Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update",
      "id": 133140400,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164745052/image_2164745052.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA. Read a portfolio update here.",
      "url": "https://finnhub.io/api/news?id=7ec5e1a10869fd2ac0edf332e5cc9731271a2844e308c8ff8479d01288fa561f"
    }
  },
  {
    "ts": null,
    "headline": "These 10 stocks beating the market’s recent Trump slump have this in common",
    "summary": "These 10 stocks beating the market’s recent Trump slump have this in common",
    "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741700400,
      "headline": "These 10 stocks beating the market’s recent Trump slump have this in common",
      "id": 133136678,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "These 10 stocks beating the market’s recent Trump slump have this in common",
      "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Mar 11, 2025",
    "summary": "Companies in The News Are: VRTX, TSLA, NVDA, COIN",
    "url": "https://finnhub.io/api/news?id=9227bc8febe3e99f1595de6d14c9204f10d98efa745c9337848ee11f897e2817",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741699320,
      "headline": "Company News for Mar 11, 2025",
      "id": 133185500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Companies in The News Are: VRTX, TSLA, NVDA, COIN",
      "url": "https://finnhub.io/api/news?id=9227bc8febe3e99f1595de6d14c9204f10d98efa745c9337848ee11f897e2817"
    }
  },
  {
    "ts": null,
    "headline": "Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever",
    "summary": "The Nasdaq Composite Index (NASDAQINDEX: ^IXIC) is now squarely in correction territory.  Here are my picks for the two smartest stocks to buy during the current Nasdaq correction and hold forever.  Amazon (NASDAQ: AMZN) stock has been hit especially hard in the latest market sell-off.",
    "url": "https://finnhub.io/api/news?id=ec907998fe65639b19d62a8f05744d4959c5ddd08e3b2c50ca4912ea9dba717c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741685460,
      "headline": "Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever",
      "id": 133185501,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Nasdaq Composite Index (NASDAQINDEX: ^IXIC) is now squarely in correction territory.  Here are my picks for the two smartest stocks to buy during the current Nasdaq correction and hold forever.  Amazon (NASDAQ: AMZN) stock has been hit especially hard in the latest market sell-off.",
      "url": "https://finnhub.io/api/news?id=ec907998fe65639b19d62a8f05744d4959c5ddd08e3b2c50ca4912ea9dba717c"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Avoid VRTX and 1 Stock to Buy Instead",
    "summary": "Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.",
    "url": "https://finnhub.io/api/news?id=33cacc8ce5bd83ad95e7b40b577eb791a31eb3c9180bad391f6d48fa30a9bec9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741683917,
      "headline": "3 Reasons to Avoid VRTX and 1 Stock to Buy Instead",
      "id": 133185502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.",
      "url": "https://finnhub.io/api/news?id=33cacc8ce5bd83ad95e7b40b577eb791a31eb3c9180bad391f6d48fa30a9bec9"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Vertex Pharmaceuticals Be in 10 Years?",
    "summary": "The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX).  The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.  The company also showed its strengths beyond this specialty area, collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just recently.",
    "url": "https://finnhub.io/api/news?id=a2899b769ddda01dedafc02b4b0c80d657d9417c35b63ebf8685e2e3115b5f07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741681500,
      "headline": "Where Will Vertex Pharmaceuticals Be in 10 Years?",
      "id": 133185503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX).  The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.  The company also showed its strengths beyond this specialty area, collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just recently.",
      "url": "https://finnhub.io/api/news?id=a2899b769ddda01dedafc02b4b0c80d657d9417c35b63ebf8685e2e3115b5f07"
    }
  }
]